Literature DB >> 15269352

CD4(+) T-cell responses to herpes simplex virus type 2 (HSV-2) glycoprotein G are type specific and differ in symptomatic and asymptomatic HSV-2-infected individuals.

Kristina Eriksson1, Lars Bellner1, Staffan Görander2, Gun-Britt Löwhagen3, Petra Tunbäck3,2, Kristina Rydberg4, Jan-Åke Liljeqvist2.   

Abstract

T-cell recognition of the secreted and membrane-bound portions of the herpes simplex virus type 2 (HSV-2) glycoprotein G (sgG-2 and mgG-2, respectively) was compared in symptomatic and asymptomatic HSV-2-infected individuals and in HSV-2-seronegative controls and the responses with HSV-1 glycoproteins C and E (gC-1 and gE-1) were compared. CD4(+) T cells from HSV-2-infected individuals specifically recognized both sgG-2 and mgG-2, whereas HSV-1-infected and HSV-seronegative controls did not respond to these glycoproteins. The responses to gC-1 and gE-1, on the other hand, were not type specific, as blood mononuclear cells from both HSV-1- and HSV-2-infected individuals responded in vitro. There was an association between the status of the infection (symptomatic versus asymptomatic) and the CD4(+) T-cell responsiveness. Symptomatic HSV-2-seropositive individuals responded with significantly lower Th1 cytokine production to sgG-2 and mgG-2 than did asymptomatic HSV-2-infected carriers, especially within the HSV-1-negative cohort. No differences in T-cell proliferation were observed between asymptomatic and symptomatic individuals. The results have implications for studies of HSV-2-specific CD4(+) T-cell reactivity in general and for analysis of immunological differences between asymptomatic and symptomatic individuals in particular.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15269352     DOI: 10.1099/vir.0.79978-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

1.  Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine.

Authors:  Xavier Dervillez; Chetan Gottimukkala; Khaled W Kabbara; Chelsea Nguyen; Tina Badakhshan; Sarah M Kim; Anthony B Nesburn; Steven L Wechsler; Lbachir Benmohamed
Journal:  Future Virol       Date:  2012-04-01       Impact factor: 1.831

2.  Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.

Authors:  Staffan Görander; Ali M Harandi; Madelene Lindqvist; Tomas Bergström; Jan-Åke Liljeqvist
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

3.  STAT4 regulates antiviral gamma interferon responses and recurrent disease during herpes simplex virus 2 infection.

Authors:  Alexandra Svensson; Petra Tunbäck; Inger Nordström; Andrey Shestakov; Leonid Padyukov; Kristina Eriksson
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

4.  Inhibition of γ-secretase cleavage in the notch signaling pathway blocks HSV-2-induced type I and type II interferon production.

Authors:  Alexandra Svensson; Emely Jäkärä; Andrey Shestakov; Kristina Eriksson
Journal:  Viral Immunol       Date:  2010-12       Impact factor: 2.257

5.  Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B.

Authors:  Aziz Alami Chentoufi; Nicholas R Binder; Noureddine Berka; Guillaume Durand; Alex Nguyen; Ilham Bettahi; Bernard Maillère; Lbachir BenMohamed
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

6.  Associations of Viral Seroreactivity with AIDS-Related Non-Hodgkin Lymphoma.

Authors:  Minkyo Song; Bryan A Bassig; Noemi Bender; James J Goedert; Cheryl A Winkler; Nicole Brenner; Tim Waterboer; Charles S Rabkin
Journal:  AIDS Res Hum Retroviruses       Date:  2020-03-02       Impact factor: 2.205

Review 7.  Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown.

Authors:  Aziz Alami Chentoufi; Elizabeth Kritzer; David M Yu; Anthony B Nesburn; Lbachir Benmohamed
Journal:  Clin Dev Immunol       Date:  2012-03-26

Review 8.  Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections.

Authors:  Aziz Alami Chentoufi; Lbachir Benmohamed
Journal:  Clin Dev Immunol       Date:  2012-12-24

Review 9.  Mucosal resident memory CD4 T cells in protection and immunopathology.

Authors:  Damian Lanz Turner; Donna L Farber
Journal:  Front Immunol       Date:  2014-07-14       Impact factor: 7.561

10.  Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.

Authors:  Karin Önnheim; Maria Ekblad; Staffan Görander; Tomas Bergström; Jan-Åke Liljeqvist
Journal:  Viruses       Date:  2016-04-22       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.